6-Acetylmorphine



Compound IDCDAMM00131
Common name6-Acetylmorphine
IUPAC name[(4R,4aR,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] acetate
Molecular formulaC19H21NO4

Experimental data

Retention time34.55
Adduct[M+H]+
Actual mz328.154
Theoretical mz328.154
Error0.7
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score5.5865

Identifiers and class information

Inchi keyJJGYGPZNTOPXGV-UHFFFAOYNA-N
SmilesCC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3C
SuperclassAlkaloids and derivatives
ClassMorphinans

Pharmacokinetic properties

Number of descriptor values(#stars)0
Number of non-conjugated amine groups (#amine)1
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)2
Number of reactive functional groups (#rtvFG)1
Predicted central nervous system activity (CNS)1
Molecular weight (mol_MW)327.379
Computed dipole moment(dipole)4.935
Total solvent accessible surface area (SASA)542.901
Hydrophobic component of SASA (FOSA)307.924
Hydrophilic component of SASA (FISA)92.884
Pie component of the SASA (PISA)142.093
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)989.522
Number of hydrogen bond donors (donorHB)1
Number of hydrogen bond acceptors (accptHB)5.5
Free energy of solvation of dipole (dip^2/V)0.0246164
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0101308
Globularity descriptor (glob)0.884562
Predicted polarizability in cubic angstroms (QPpolrz)33.519
Predicted hexadecane/gas partition coefficient (QPlogPC16)9.42
Predicted octanol/gas partition coefficient (QPlogPoct)15.549
Predicted water/gas partition coefficient (QPlogPw)9.065
Predicted octanol/water partition coefficient (QPlogPo/w)1.731
Predicted aqueous solubility (QPlogS)-2.535
Conformation-independent predicted aqueous solubility (CIQPlogS)-3.193
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-4.804
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)325.075
Predicted brain/blood partition coefficient (QPlogBB)0.05
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)162.458
Predicted skin permeability, log Kp (QPlogKp)-4.601
PM3 calculated ionization potential (IP(ev))8.753
PM3 calculated electron affinity (EA(eV))-0.168
Number of likely metabolic reactions (#metab)5
Prediction of binding to human serum albumin (QPlogKhsa)0.189
Predicted qualitative human oral absorption (HumanOralAbsorption)3
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)82.042
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)71.238
Number of nitrogen and oxygen atoms (#NandO)5
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P35372OPRM1Mu opioid receptorT47768SEA
P41145OPRK1Kappa Opioid receptorT60693SEA
P41143OPRD1Delta opioid receptorT58992SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T47768DI0013Acute pain[ICD-11: MG31]P35372OPRM1
T47768DI0059Bowel habit change[ICD-11: ME05]P35372OPRM1
T47768DI0087Chronic pain[ICD-11: MG30]P35372OPRM1
T47768DI0101Corneal disease[ICD-11: 9A76-9A78]P35372OPRM1
T47768DI0105Cough[ICD-11: MD12]P35372OPRM1
T47768DI0117Depression[ICD-11: 6A70-6A7Z]P35372OPRM1
T47768DI0124Digestive system disease[ICD-11: DE2Z]P35372OPRM1
T47768DI0218Irritable bowel syndrome[ICD-11: DD91]P35372OPRM1
T47768DI0228Large intestine motility disorder[ICD-11: DB32]P35372OPRM1
T47768DI0317Opioid use disorder[ICD-11: 6C43]P35372OPRM1
T47768DI0324Pain[ICD-11: MG30-MG3Z]P35372OPRM1
T47768DI0349Pruritus[ICD-11: EC90]P35372OPRM1
T47768DI0374Sensation disturbance[ICD-11: MB40]P35372OPRM1
T60693DI0304Non-specific cutaneous vascular symptom[ICD-11: ME64]P41145OPRK1
T60693DI0324Pain[ICD-11: MG30-MG3Z]P41145OPRK1
T60693DI0349Pruritus[ICD-11: EC90]P41145OPRK1
T58992DI0059Bowel habit change[ICD-11: ME05]P41143OPRD1
T58992DI0218Irritable bowel syndrome[ICD-11: DD91]P41143OPRD1
T58992DI0324Pain[ICD-11: MG30-MG3Z]P41143OPRD1

Copyright © 2025